The study suggests “software monitoring may help reduce the duration and severity of intraoperative hypotension.”
Edwards software linked to improved blood pressure control during surgery Read More »
The company recalled all products made at its Boston facility over the last five years, and hopes to restart manufacturing in the fourth quarter.
Integra receives warning letter related to quality issues at Boston plant Read More »
The global precision oncology market size is estimated to grow from USD 1,00,060 million in 2022 to reach around USD 2,58,350 million by 2032, growing at a CAGR of 9.9% from 2023 to 2032, A study published by Towards Healthcare.
Precision Oncology Market Size is Projected to Reach USD 2,58,350 Million By 2032 Read More »
Coeptis Therapeutics Holdings, Inc. announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. (“Deverra”) related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages.
Cybin Inc. today announced that it has initiated preparations for good manufacturing practices (“GMP”) production of a capsule formulation of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder (“MDD”).
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial Read More »
Akston Biosciences Corporation announced today that it will focus on inventing, developing, and manufacturing breakthrough protein therapeutics for Companion Animal Health, utilizing its versatile Ambifect™ Fc-fusion platform and its Beverly, Massachusetts cGMP biologics manufacturing facility.
Akston Biosciences to Focus on Strong Animal Health Pipeline Read More »
Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate atopic dermatitis.
Foresight Diagnostics, a leading provider of ultrasensitive cancer detection tests, today announced the appointment of John Truesdell as Chief Business Officer.
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today provided first half, 2023, financial results and operational highlights.
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights Read More »
Dizal will present the results of a molecular analysis on EGFR Exon20ins mutations in tumor tissue and plasma ctDNA using next-generation sequencing, and their correlation with clinical activity observed in patients treated with sunvozertinib, in a mini oral presentation at the 2023 World Conference on Lung Cancer, taking place September 9 – 12, 2023 in
